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ABSTRACT
Effective treatment options for advanced salivary gland tumors are lacking. To 
better understand these tumors, we report their genomic landscape. We studied 
the molecular aberrations in 117 patients with salivary gland tumors that were, on 
physician request, tested in a Clinical Laboratory Improvement Amendments (CLIA) 
laboratory (Foundation Medicine, Cambridge, MA) using next-generation sequencing 
(182 or 236 genes), and analyzed by N-of-One, Inc. (Lexington, MA). There were 354 
total aberrations, with 240 distinct aberrations identified in this patient population. 
Only 10 individuals (8.5%) had a molecular portfolio that was identical to any other 
patient (with four different portfolios amongst the ten patients).
The most common abnormalities involved the TP53 gene (36/117 [30.8% of 
patients]), cyclin pathway (CCND1, CDK4/6 or CDKN2A/B) (31/117 [26.5%]) and 
PI3K pathway (PIK3CA, PIK3R1, PTEN or AKT1/3) (28/117 [23.9%]). In multivariate 
analysis, statistically significant co-existing aberrations were observed as follows: 
TP53 and ERBB2 (p = 0.01), cyclin pathway and MDM2 (p = 0.03), and PI3K pathway 
and HRAS (p = 0.0001). We were able to identify possible cognate targeted therapies 
in most of the patients (107/117 [91.5%]), including FDA-approved drugs in 80/117 
[68.4%]. In conclusion, salivary gland tumors were characterized by multiple distinct 
aberrations that mostly differed from patient to patient. Significant associations 
between aberrations in TP53 and ERBB2, the cyclin pathway and MDM2, and HRAS 
and the PI3K pathway were identified. Most patients had actionable alterations. These 
results provide a framework for tailored combinations of matched therapies.
INTRODUCTION
Malignant salivary gland tumors are an 
uncommon subgroup of head and neck cancers [1–3]. 
The most frequent types of malignant salivary gland 
tumors according to the WHO classification [1] are 
mucoepidermoid carcinoma (10.0–32.7%) and adenoid 
cystic carcinoma (23.3–23.8%) [4, 5].
Initial standard of care therapy of localized disease 
is surgery and/or radiation therapy, whereas chemotherapy 
is typically reserved for palliative treatment of local and 
regional recurrence or metastatic disease [6]. Due to the 
rarity of the disease, data are often derived from case 
reports and retrospective series, rather than prospectively 
performed clinical trials. Thus, it has been challenging to 
define the role of chemotherapy in management of advanced 
salivary gland tumors [6]. Systemic therapies investigated 
in the past include cisplatin [7], paclitaxel [8], combination 
of cisplatin plus vinorelbine [9] and the combination 
of cisplatin, doxorubicin and cyclophosphamide [10]. 
Modest response rates can be achieved with cytotoxic 
chemotherapy (~4% to 27%) [7–10] and no drugs are 
approved by the Food and Drug Administration (FDA) 
specifically for salivary gland tumors.
Importantly, several possible biological targets 
in salivary gland tumors have been reported: c-Kit[11] 
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(positive protein expression by immunohistochemistry but 
no exon 11 or 17 mutations); EGFR [12], HER2 [13, 14], 
androgen, estrogen and progesterone receptor protein 
expression by immunohistochemistry [15]; and PIK3CA 
[16] and BRAF mutations [16]. Interestingly, salivary 
duct carcinomas resemble breast cancer histologically, 
and about 20 to 80% of salivary duct carcinomas are 
HER2 positive by immunohistochemistry [13, 14]; in 
approximately 90% of salivary duct carcinomas, androgen 
receptors are positive by immunohistochemistry [17].
Although targeted therapies with imatinib [18], 
gefitinib [19], cetuximab [20], trastuzumab [21] and 
lapatinib [22] have generally had low response rates, 
these therapies were given to unselected patients rather 
than matched to individuals whose tumors harbored 
cognate aberrations [18–22]. However, when patients were 
selected for the presence of ERBB2/HER2 or PIK3CA 
aberrations and were treated with appropriate targeting 
agents (trastuzumab and lapatinib [23] or mTOR inhibitors 
[24], respectively), anecdotal remarkable responses have 
been described.
Given that effective treatment options are needed, 
further molecular understanding of salivary gland 
tumors is necessary. We therefore examined the genomic 
landscape of salivary gland malignancies, as determined 
by targeted next-generation sequencing (NGS). Here we 
report the most frequent aberrations, many of which could 
conceivably be actionable with targeted therapies.
RESULTS
Genetic aberrations in salivary gland tumors 
(Table 1, Figure 1 and Supplemental Table 1)
Among all salivary gland tumors (N = 117) 
that were evaluated, 41.9% (49/117) of samples were 
histologically diagnosed as adenoid cystic carcinoma. The 
second most common histology was adenocarcinoma, not 
otherwise specified (NOS) (39.3% [46/117]) followed by 
acinic cell carcinoma (6.0% [7/117]), mucoepidermoid 
carcinoma (4.3% [5/117]), salivary duct carcinoma 
(3.4% [4/117]), myoepithelial carcinoma (2.6% [3/117]) 
and undifferentiated carcinoma (2.6% [3/117]) (Table 1).
The most common aberration among all salivary 
gland tumors was in the TP53 gene (36/117 patients 
[30.8%]), followed by anomalies in the cyclin pathway 
(CCND1, CDK4/6 or CDKN2A/B) (observed in 26.5% 
[31/117] of all salivary gland tumors). Aberrations in the 
PI3K pathway (PIK3CA, PIK3R1, PTEN or AKT) were the 
third most common set of aberrations among all salivary 
gland tumors (28/117 [23.9%]). Anomalies in HRAS 
were seen in 11.1% (13/117) of salivary gland tumors, 
including 5 of 46 patients (10.9%) with adenocarcinoma, 
NOS (Table 1 and Figures 1A and 1C). Aberrations in 
ERBB2 were found only in patients with adenocarcinoma, 
NOS (7/46 patients [15.2%] [two mutations and five 
amplifications]) (Table 1 and Figure 1C).
Molecular characteristics of patients with 
adenocarcinoma, NOS (N = 46) were similar to those of 
all salivary gland tumors (Table 1 and Figures 1A and 1C), 
likely because they were the second most common 
subgroup. The most common genetic aberrations among 
patients with adenoid cystic carcinoma (N = 49) were 
NOTCH1/2 (26.5% [13/49]) (mainly NOTCH1 (24.5% 
[12/49])) and KDM6A (26.5% [13/49]). Aberrations in the 
PI3K pathway represent the second most common genetic 
alterations in adenoid cystic carcinoma patients (16.3% 
[8/49]) (Table 1 and Figure 1B).
Number of genetic aberrations and possible 
cognate targeted therapies in patients with 
salivary gland tumors (Figure 2, Supplemental 
Tables 1 and 2)
Of the 354 total aberrations (some aberrations 
were identified in more than one case), 257 (72.6%) 
were actionable, with 107/117 patients (91.5%) having 
a potentially actionable abnormality. Of the 240 distinct 
aberrations, 155 (64.6%) were potentially actionable. Of 
these 155 actionable aberrations, 114 (47.5% [114/240]) 
were targetable by an FDA-approved drug (off label). 
An additional 41 (17.1% [41/240]) were targetable by an 
experimental drug in a clinical trial. The number of genetic 
aberrations reported per patient ranged from zero to ten 
with a median of three aberrations per patient (Figure 2). 
The number of genetic aberrations that were actionable 
ranged from zero to ten with a median of two actionable 
aberrations per patient (Figure 2). Of the 107 patients 
with at least one actionable aberration, 80 (74.8%) had 
an aberration targetable by an FDA-approved drug and 
an additional 27 (25.2%) had an aberration targetable by 
an investigational drug in a clinical trial (Supplemental 
Tables 1 and 2).
Number of genomic aberrations and the 
distinctness of the profiles
As mentioned, there were 240 distinct molecular 
alterations. Only ten patients (8.5% [10/117]) had 
a molecular portfolio identical to at least one other 
patient (Supplemental Table 1, Case No. 13 and 1297 
([both adenocarcinoma, not otherwise specified]; 
No. 1523 and 1777 [both adenocarcinoma, not otherwise 
specified]; No. 3808, 4033, 4051 and 5681 [first three 
cases with acinic cell carcinoma and last past patient 
had adenocarcinoma, not otherwise specified]; and No. 
1169 and 2807 [both adenoid cystic carcinoma] were 
identical). If we considered the molecular portfolio at 
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the level of the gene, rather than the specific aberration 
(i.e., different abnormalities in the same gene would be 
considered identical), then the total number of genes 
altered across this cohort was 83 and, in that case, 20 
patients (17.1% [20/117]) had an identical molecular 
portfolio to at least one other patient (Supplemental 
Table 1, Case No. 13 and 1297; No. 1169 and 2807; No. 
1523 and 1777; No. 1939 and 6651; No. 1975 and 5730; 
No. 2085 and 6718; No. 2901 and 4533; No. 3808, 4033, 
and 5681; and No. 4332 and 4731 were identical).
Association between TP53 and co-existing 
molecular aberrations in patients with salivary 
gland tumors. Univariate and multivariate 
analysis (Table 2)
In univariate analysis, NF1 aberrations were found 
to be significantly associated with TP53 aberrations 
(6 of 8 patients [75.0%] with aberrant NF1 had a TP53 
aberration; 30 of 109 patients [27.5%] with normal NF1 
had a TP53 aberration; p = 0.01). Anomalies in the PI3K 
Table 1: Baseline characteristics of salivary gland tumors and frequently associated genetic 
aberrations
Genetic 
aberrations*
All  
N = 117  
No. (%)
Adenoid 
cystic 
carcinoma 
N = 49 
No. (%)
Adeno-
carcinoma, 
not 
otherwise 
specified 
N = 46 
No. (%)
Aciniccell 
carcinoma 
N = 7 
No. (%)
Muco-
epidermoid 
carcinoma 
N = 5 
No. (%)
Salivary 
duct 
carcinoma 
N = 4 
No. (%)
Myoepithelial 
carcinoma 
N = 3 
No. (%)
Un-
differeniated 
carcinoma 
N = 3 
No. (%)
TP53  
(N = 36)
36 
(30.8) 7 (14.3) 23 (50.0) 1 (14.3) 2 (40.0) 2 (50) 0 (0) 1 (33.3)
Cyclin pathway# 
(N = 31)
31 
(26.5) 6 (12.2) 16 (34.8) 5 (71.4) 1 (20.0) 0 (0) 1 (33.3) 2 (66.7)
PI3K pathway¥ 
(N = 28)
28 
(23.9) 8 (16.3) 12 (26.1) 1 (14.3) 2 (40.0) 4 (100) 1 (33.3) 0 (0)
NOTCH1/2  
(N = 20)
20 
(17.1) 13 (26.5) 6 (13.0) 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0)
PIK3CA 
(N = 16)
16 
(13.7) 3 (6.1) 8 (17.4) 1 (14.3) 1 (20.0) 2 (50) 1 (33.3) 0 (0)
KDM6A 
(N = 14)
14 
(12.0) 13 (26.5) 1 (2.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ARID1A 
(N = 13) 13 (11.1) 7 (14.3) 5 (10.9) 0 (0) 1 (20.0) 0 (0) 0 (0) 0 (0)
HRAS  
(N = 13) 13 (11.1) 2 (4.1) 5 (10.9) 1 (14.3) 1 (20.0) 2 (50) 2 (66.7) 0 (0)
BAP1 
 (N = 10) 10 (8.5) 4 (8.2) 3 (6.5) 1 (14.3) 2 (40.0) 0 (0) 0 (0) 0 (0)
MDM2  
(N = 10) 10 (8.5) 2 (4.1) 7 (15.2) 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3)
PTEN 
 (N = 10) 10 (8.5) 2 (4.1) 5 (10.9) 0 (0) 2 (40.0) 1 (25) 0 (0) 0 (0)
NF1  
(N = 8) 8 (6.8) 0 (0) 6 (13.0) 1 (14.3) 1 (20.0) 0 (0) 0 (0) 0 (0)
ERBB2  
(N = 7) 7 (6.0) 0 (0) 7 (15.2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
*Genetic aberrations with N ≥ 7 are reported.
#Cyclin pathway aberrations included CCND1, CDK4/6 or CDKN2A/B aberrations.
¥PI3K pathway aberrations included PIK3CA, PIK3R1, PTEN or AKT1/3 aberrations.
Oncotarget25634www.impactjournals.com/oncotarget
#Cyclin pathway aberrations included CCND1, CDK4/6 or CDKN2A/B aberrations.
¥PI3K pathway aberrations included PIK3CA, PIK3R1, PTEN or AKT1/3 aberrations. 
*Other: Genetic aberration with N = 1.
A. Genetic aberrations in patients with salivary gland tumors (N = 117) 
Oncotarget25635www.impactjournals.com/oncotarget
¥PI3K pathway aberrations included PIK3CA, PIK3R1, PTEN or AKT1/3 aberrations.
#Cyclin pathway aberrations included CCND1, CDK4/6 or CDKN2A/B aberrations.
*Other: Genetic aberration with N = 1. 
#Cyclin pathway aberrations included CCND1, CDK4/6 or CDKN2A/B aberrations.
¥PI3K pathway aberrations included PIK3CA, PIK3R1, PTEN or AKT1/3 aberrations.
* Other: Genetic aberration with N = 1.
B. Frequently associated genetic aberrations in patients with adenoid cystic carcinoma (N = 49)
C. Frequently associated genetic aberrations in patients with salivary gland adenocarcinoma, not otherwise specified (N = 46)
Figure 1: Genetic aberrations in patients with all salivary gland tumors (N = 117). (A) adenoid cystic carcinoma 
(N = 49) (B) and in patients with adenocarcinoma, not otherwise specified (N = 46) (C).
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Figure 2: Number of reported genetic aberrations and number of theoretically actionable genetic aberrations per 
patient. Of the 354 total aberrations (some aberrations may have been found in more than one person), 257 were actionable, with 107/117 
of patients (91.5%) having a potentially actionable abnormality. Of the 240 distinct aberrations, 155 (64.6%) were potentially actionable. 
An aberration was considered potentially actionable if there is a drug that is approved or in clinical trials that targets that aberration with 
low nM IC50 or an antibody that primarily targets that abnormality.
Oncotarget25637www.impactjournals.com/oncotarget
Table 2: Association between TP53 aberration and co-existing molecular aberrations in patients 
with salivary gland tumors (N = 117)
Patient characteristics  
N = 117
Aberrant TP53  
N = 36 (%)
Normal TP53  
N = 81 (%)
p-value*  
Univariate
p-value¶  
Multivariate
Co-existing aberrations§
Cyclin pathway# 0.82
 Aberrant (N = 31) 10 (32.3) 21 (67.7)
 Wild-type (N = 86) 26 (30.2) 60 (69.8)
PI3K pathway¥ 0.06 0.04
 Aberrant (N = 28) 13 (46.4) 15 (53.6)
 Wild-type (N = 89) 23 (25.8) 66 (74.2)
NOTCH1/2 0.11
 Aberrant (N = 20) 3 (15.0) 17 (85.0)
 Wild-type (N = 97) 33 (34.0) 64 (66.0)
PIK3CA 0.25
 Aberrant (N = 16) 7 (43.8) 9 (56.3)
 Wild-type (N = 101) 29 (28.7) 72 (71.3)
KDM6A 0.55
 Aberrant (N = 14) 3 (21.4) 11 (78.6)
 Wild-type (N = 103) 33 (32.0) 70 (68.0)
ARID1A 0.75
 Aberrant (N = 13) 3 (23.1) 10 (76.9)
 Wild-type (N = 104) 33 (31.7) 71 (68.3)
HRAS 0.22
 Aberrant (N = 13) 6 (46.2) 7 (53.8)
 Wild-type (N = 104) 30 (28.8) 74 (71.2)
BAP1 0.49
 Aberrant (N = 10) 4 (40.0) 6 (60.0)
 Wild-type (N = 107) 32 (29.9) 75 (70.1)
MDM2 0.17
 Aberrant (N = 10) 1 (10.0) 9 (90.0)
 Wild-type (N = 107) 35 (32.7) 72 (67.3)
NF1 0.01 0.07
 Aberrant (N = 8) 6 (75.0) 2 (25.0)
 Wild-type (N = 109) 30 (27.5) 79 (72.5)
ERBB2 0.003 0.01
 Aberrant (N = 7) 6 (85.7) 1 (14.3)
 Wild-type (N = 110) 30 (27.3) 80 (72.7)
*p-values are from Fisher’s exact test.
¶p < 0.1 from univariate analysis were included in multivariate analysis using multiple logistic regression models.
§Included characteristics with N ≥ 7 of genetic aberration.
#Cyclin pathway aberrations included CCND1, CDK4/6 or CDKN2A/B aberrations.
¥PI3K pathway aberrations included PIK3CA, PIK3R1, PTEN or AKT1/3 aberrations.
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pathway (PIK3CA, PIK3R1, PTEN or AKT1/3) were also 
found to be associated with TP53 aberrations (13 of 28 
patients [46.4%] with anomalies in PI3K pathway had a 
TP53 aberration; 23 of 89 patients [25.8%] with normal 
PI3K pathway had a TP53 aberration; p = 0.06 [trend]). 
Interestingly, ERBB2 aberrations were also associated 
with TP53 aberrations (6 of 7 patients [85.7%] with 
aberrant ERBB2 had a TP53 aberration; 30 of 110 patients 
[27.3%] with normal ERBB2 had a TP53 aberration; 
p = 0.003).
After multivariate analysis, anomalies in the 
PI3K pathway and ERBB2 aberrations were found to 
have an increased association with TP53 aberrations 
(p = 0.04 and 0.01 respectively) (Table 2).
Association between aberrant cyclin pathway 
(CCND1, CDK4/6 or CDKN2A/B) and co-existing 
molecular aberrations. Univariate and 
multivariate analysis (Table 3)
In univariate analysis, there was a negative 
association between aberrant cyclin pathway and aberrant 
NOTCH1/2 (2 of 20 patients [10.0%] with aberrant 
NOTCH1/2 had an abnormality in cyclin pathway; 
29 of 97 patients [29.9%] with normal NOTCH1/2 had 
an abnormality in cyclin pathway; p = 0.09 [trend]). 
Presence of an MDM2 aberration was associated with 
abnormalities in cyclin pathway by univariate analysis 
(6 of 10 patients [60.0%] with aberrant MDM2 had 
an abnormality in cyclin pathway; 25 of 107 patients 
[23.4%] with normal MDM2 had an abnormality in cyclin 
pathway; p = 0.02).
After multivariate analysis, aberrations in MDM2 
remain positively associated with an aberrant cyclin 
pathway (p = 0.03) (Table 3).
Association between PI3K pathway abnormalities 
(PIK3CA, PTEN, AKT1/3 aberrations) and  
co-existing molecular aberrations. Univariate 
and multivariate analysis (Table 4)
In univariate analysis, aberrations in HRAS were 
associated with PI3K pathway abnormalities (10 of 
13 patients [76.9%] with aberrant HRAS had a PI3K 
pathway abnormality; 18 of 104 patients [17.3%] 
with normal HRAS had a PI3K pathway abnormality; 
p = < 0.0001).
A trend toward an association between aberrations 
in NF1 and PI3K pathway abnormalities was noted (4 of 
8 patients [50.0%] with aberrant NF1 had an abnormality 
in the PI3K pathway; 24 of 109 patients [22.0%] with 
normal NF1 had an abnormality in PI3K pathway; 
p = 0.09 [trend]). As mentioned earlier (Table 2), there 
was a positive correlation between PI3K pathway 
abnormalities and aberrant TP53 (13 of 36 patients 
[36.1%] with aberrant TP53 had an abnormality in the 
PI3K pathway; 15 of 81 patients [18.5%] with normal 
TP53 had an abnormality in the PI3K pathway; p = 0.06 
[trend]).
The correlation between aberrant TP53 and PI3K 
pathway was no longer seen after multivariate analysis 
(Tables 2 and 4). However, the association between 
aberrant HRAS and PI3K pathway abnormalities remained 
statistically significant (p = 0.0001) (Table 4).
DISCUSSION
Malignant salivary gland tumors are an uncommon 
type of cancer of the head and neck [1, 2]. In general, 
salivary gland tumors have shown low response rates to 
chemotherapies [7–10] or to molecularly targeted therapies 
that are administered without molecular matching [11–13, 
15, 16, 18–22]. Thus, therapeutic options for salivary 
gland tumors are limited. However, anecdotal reports 
have described remarkable responses in salivary tumors 
when genetic aberrations and therapies were matched: 
trastuzumab and lapatinib for Her2-aberrant salivary 
tumors [23] or mTOR inhibitors for PIK3CA-aberrant 
neoplasms [24]. We therefore investigated the genomic 
landscape of salivary gland tumors by targeted next-
generation sequencing.
In our current study of 117 patients suffering from 
salivary gland tumors, the most common histological 
diagnosis was adenoid cystic carcinoma (41.9% [49/117]). 
The second most common histology was adenocarcinoma, 
NOS (39.3% [46/117]) followed by acinic cell carcinoma 
(6.0% [7/117]) and mucoepidermoid carcinoma (4.3% 
[5/117]) (Table 1).
It is unclear why the frequency of histological 
subtypes of salivary gland tumors seen in this study is 
different from the previous literature; mucoepidermoid 
carcinoma and adenoid cystic carcinoma are the two most 
common subtypes [4, 5] and adenocarcinoma, NOS has 
been reported to be relatively low in frequency (1.8 - 3.3%) 
[4, 5]. However it is plausible that aggressive histological 
subtypes of malignant salivary gland tumors are more 
frequently referred for next-generation sequencing in order 
to pursue possible treatment options. Indeed, Wahlberg 
et al reported that patients with adenocarcinoma, NOS had 
worse 10-year survival compared to mucoepidermoid and 
adenoid cystic carcinoma (10-year survival 55%, 80%, 
and 74% respectively) [3].
The most common genetic aberration among 
117 patients with salivary gland tumors was TP53 mutation 
(36/117 [30.8%]) (Table 1, Figure 1A and Supplemental 
Table 1). Our current study is in agreement with previous 
reports demonstrating that 22–60% of salivary gland 
tumors harbor a TP53 mutation [25–27]. Although little 
is known about the role of TP53 in the pathogenesis 
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Table 3: Association between aberrant cyclin pathway (CCND1, CDK4/6 or CDKN2A/B) and 
co-existing molecular aberration in patients with salivary gland tumor (N = 117)
Patient characteristics  
N = 117
Aberrant cyclin 
pathway 
N = 31 (%)
Normal cyclin  
pathway N = 86 (%)
p-value*  
Univariate
p-value¶  
Multivariate
Co-existing aberrations§
TP53 0.82
 Aberrant (N = 36) 10 (27.8) 26 (72.2)
 Wild-type (N = 81) 21 (25.9) 60 (74.1)
PI3K pathway¥ 0.33
 Aberrant (N = 28) 5 (17.9) 23 (82.1)
 Wild-type (N = 89) 26 (29.2) 63 (70.8)
NOTCH1/2 0.09 0.10
 Aberrant (N = 20) 2 (10.0) 18 (90.0)
 Wild-type (N = 97) 29 (29.9) 68 (70.1)
PIK3CA 0.55
 Aberrant (N = 16) 3 (18.8) 13 (81.3)
 Wild-type (N = 101) 28 (27.7) 73 (72.3)
KDM6A 0.11
 Aberrant (N = 14) 1 (7.1) 13 (92.9)
 Wild-type (N = 103) 30 (29.1) 73 (70.9)
ARID1A 0.18
 Aberrant (N = 13) 1 (7.7) 12 (92.3)
 Wild-type (N = 104) 30 (28.8) 74 (71.2)
HRAS 0.18
 Aberrant (N = 13) 1 (7.7) 12 (92.3)
 Wild-type (N = 104) 30 (28.8) 74 (71.2)
BAP1 0.45
 Aberrant (N = 10) 4 (40.0) 6 (60.0)
 Wild-type (N = 107) 27 (25.2) 80 (74.8)
MDM2 0.02 0.03
 Aberrant (N = 10) 6 (60.0) 4 (40.0)
 Wild-type (N = 107) 25 (23.4) 82 (76.6)
NF1 0.68
 Aberrant (N = 8) 1 (12.5) 7 (87.5)
 Wild-type (N = 109) 30 (27.5) 79 (72.5)
ERBB2 1.00
 Aberrant (N = 7) 2 (28.6) 5 (71.4)
 Wild-type (N = 110) 29 (26.4) 81 (73.6)
*p-values are from Fisher’s exact test.
¶p < 0.1 from univariate analysis were included in multivariate analysis using multiple logistic regression models.
§Included characteristics with N ≥ 7 of genetic aberration.
¥PI3K pathway aberrations included PIK3CA, PIK3R1, PTEN or AKT1/3 aberrations.
Oncotarget25640www.impactjournals.com/oncotarget
Table 4: Association between PI3K pathway abnormalities (PIK3, PIK3R1, PTEN, or AKT1/3 
aberrations) and co-existing molecular aberration in patients with salivary gland tumor (N = 117)
Patient characteristics  
N = 117
Aberrant PI3K 
pathway N = 28 (%)
Normal PI3K 
pathway N = 89 (%)
p-value*  
Univariate
p-value¶  
Multivariate
Co-existing aberrations§
TP53 0.06 0.22
 Aberrant (N = 36) 13 (36.1) 23 (63.9)
 Wild-type (N = 81) 15 (18.5) 66 (81.5)
Cyclin pathway# 0.33
 Aberrant (N = 31) 5 (16.1) 26 (83.9)
 Wild-type (N = 86) 23 (26.7) 63 (73.3)
NOTCH1/2 0.15
 Aberrant (N = 20) 2 (10.0) 18 (90.0)
 Wild-type (N = 97) 26 (26.8) 71 (73.2)
KDM6A 0.51
 Aberrant (N = 14) 2 (14.3) 12 (85.7)
 Wild-type (N = 103) 26 (25.2) 77 (74.8)
ARID1A 0.19
 Aberrant (N = 13) 1 (7.7) 12 (92.3)
 Wild-type (N = 104) 27 (26.0) 77 (74.0)
HRAS <0.0001 0.0001
 Aberrant (N = 13) 10 (76.9) 3 (23.1)
 Wild-type (N = 104) 18 (17.3) 86 (82.7)
BAP1 0.70
 Aberrant (N = 10) 3 (30.0) 7 (70.0)
 Wild-type (N = 107) 25 (23.4) 82 (76.6)
MDM2 1.00
 Aberrant (N = 10) 2 (20.0) 8 (80.0)
 Wild-type (N = 107) 26 (24.3) 81 (75.7)
NF1 0.09 0.16
 Aberrant (N = 8) 4 (50.0) 4 (50.0)
 Wild-type (N = 109) 24 (22.0) 85 (78.0)
ERBB2 1.00
 Aberrant (N = 7) 1 (14.3) 6 (85.7)
 Wild-type (N = 110) 27 (24.5) 83 (75.5)
*p-values are from Fisher’s exact test.
¶p < 0.1 from univariate analysis were included in multivariate analysis using multiple logistic regression models.
§Included characteristics with N ≥ 7 of genetic aberration.
#Cyclin pathway aberrations included CCND1, CDK4/6 or CDKN2A/B aberrations.
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of salivary gland tumors, it has been suggested that 
alteration in this gene is involved in later stages of tumor 
progression [28]. Of interest, Said et al showed that 
bevacizumab-containing regimens were associated with 
longer progression-free survival (PFS) when compared 
to non-bevacizumab-containing regimens in patients 
with TP53-mutated advanced solid tumors (median 11.0 
versus 4.0 months; PFS was not increased in patients 
with wild-type TP53 on bevacizumab-based treatment 
[median = 5 months, p < 0.0001]) [29]. These results 
require validation in a prospective study. Of interest, in our 
study, aberrations in ERBB2 were associated with TP53 
anomalies after multivariate analysis (p = 0.01) (Table 2). 
Anomalies in ERBB2 may be targeted with lapatinib or 
trastuzumab [23, 30].
The second most common aberrations involved the 
cyclin pathway (CCND1, CDK4/6 or CDKN2A/B), which 
was abnormal in 26.5% of patients (31/117) with salivary 
gland tumors. Aberrations in the cyclin D-cyclin-dependent 
kinase pathway that regulates the cell cycle restriction 
point is a common feature of human cancer, contributing to 
tumor proliferation, genomic instability and chromosomal 
instability [31–33]. This pathway can be altered through 
multiple mechanisms including increased signaling 
through CDK4 and CDK6 amplification, overexpression of 
cyclin D1, and loss of inhibitors including CDKN2A (p16) 
and/or CDKN2B (p15) [34–37]. Mutation or loss of RB1 
(Rb; retinoblastoma) also alters this pathway, but renders 
tumors resistant to CDK inhibitors. Only three patients 
in our series had RB1 mutations. According to Etges 
et al [38], malignant salivary gland tumors expressed the 
cyclin pathway differently from normal salivary gland 
when assessed by immunohistochemistry. They reported 
that expression of cyclin D1, CDK4 and CDKN2A were 
significantly higher in malignant salivary gland tumors 
(including adenoid cystic carcinoma and mucoepidermoid 
carcinoma) when compared to normal salivary gland. 
Meanwhile protein expression level of Rb was lower in 
malignant salivary gland tumors when compared to normal 
salivary gland [38]. Although it is unclear why CDKN2A 
protein expression was higher in malignant salivary 
gland tumors in this study, it is possible that the cyclin 
pathway is involved in tumorigenesis of salivary gland 
cancers. Regarding therapeutic implications, the cyclin 
pathway is possibly targetable with CDK4/6 inhibitors 
such as with palbociclib [33] and further investigation is 
warranted. Of interest, MDM2 amplifications were more 
likely to be associated with abnormalities in the cyclin 
pathway (6/10 [60.0%] versus 25/107 [23.4%]; p = 0.03 
after multivariate analysis) (Table 3). Similarly, Moller 
et al reported that five out of seven patients with diffuse 
large B cell lymphomas had co-aberrations in MDM2 
(amplification) and CDKN2A (deletion), when assessed 
by immunohistochemistry and polymerase chain reaction 
respectively [39]. Since MDM2 is negatively regulated 
by CDKN2A, MDM2 amplification and aberrations in the 
cyclin pathway will likely lead to suppression of TP53 
(TP53 is negatively regulated by MDM2) [40]. Thus, 
for patients with co-aberrations in MDM2 and the CDK 
pathway, inhibition of both MDM2 [41] and the cyclin 
pathway [33] may be required to effectively target this 
pathway.
Importantly, aberrations in the PI3K pathway 
(PIK3CA, PIK3R1, PTEN or AKT) were commonly seen in 
salivary gland tumors (28/117 [23.9%]). Of interest, there 
was a statistically significant association between aberrant 
HRAS and PI3K pathway abnormalities (10/13 [76.9%] 
versus 18/104 [17.3%]; p = 0.0001 after multivariate 
analysis, Table 4). PI3K and RAS are key regulators of 
cell motility and chemotaxis and they influence each 
other’s activities by direct and indirect feedback processes 
[42]. Janku et al have also previously shown that MAP 
(mitogen-activated protein) kinase-related genes are more 
frequently aberrant in the presence PIK3CA mutations 
than when PIK3CA is normal [43]. Since mutation in 
HRAS is also capable of activating the MAP kinase 
signaling pathway, merely blocking the PI3K pathway 
will likely not be sufficient. Although the role of PIK3CA 
mutation as a predictive biomarker for everolimus 
or PI3K inhibitor response is controversial [44], the 
PI3K pathway is potentially targetable with the mTOR 
inhibitor everolimus [45]. Adding MEK inhibitors such as 
trametanib [46] in order to block signals downstream of 
HRAS may be required in patients who have anomalies in 
the PI3K pathway.
Our results in adenoid cystic carcinoma (Figure 1B) 
are in agreement with previously reported literature where 
several aberrations including NOTCH1/2 (3/24 [12.5%]), 
KDM6A (2/24 [8.3%]), CDKN2A (1/24 [4.2%]) and 
PIK3CA (1/24 [4.2%]) were identified by whole exome 
sequencing of 24 patients with adenoid cystic carcinoma 
[47]. Both studies had small numbers of patients, reflecting 
the rarity of this tumor.
Interestingly, 107/117 patients (91.5%) had 
potentially actionable aberrations (Supplemental Table 1). 
The number of actionable genes affected per patient ranged 
between zero and ten, with a median of two per patient 
(Figure 2). Of the 240 distinct aberrations, 155 (64.6%) 
were potentially actionable. Of these 155 actionable 
aberrations, 114 were targetable by an FDA-approved 
drug (off label) (representing 47.5% [114/240] of all 
distinct alterations). An additional 41 (17.1% [41/240] of 
all distinct alterations) were targetable by an experimental 
drug in a clinical trial. (Figure 2, Supplemental Table 1 
and 2). Overall, 91.5% (107/117) of patients had at least 
one potentially actionable anomaly. As there are no FDA-
approved targeted therapies for salivary gland tumors and 
most conventional chemotherapy has been shown to be 
associated with poor clinical outcomes (median overall 
survival [OS]: 4 to 21 months in the advanced setting) 
[7–10], targeted therapies based on molecular profiling 
merit investigation [48].
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Our current study has some limitations. First, it 
was performed retrospectively with a relatively limited 
number of patients, especially in certain subgroups of 
salivary gland tumors. The small numbers preclude 
definitive statistical conclusions in some areas. Second, 
multiple comparisons could result in overcalling the 
implications of positive p values. Third, we included 
heterogeneous salivary gland tumors. Fourth, molecular 
analysis was performed on archival tumor tissue, which 
was obtained at a different time points in relationship to 
the clinical history. Lastly, lumping the common pathway 
abnormalities together such as cyclin pathway (CCND1, 
CDK4/6 or CDKN2A/B) and PI3K pathway (PIK3CA, 
PIK3R1, PTEN or AKT1/3) aberrations may be misleading 
since different mutations can lead to diverse functional 
consequences. However, despite these limitations, this 
genomic characterization of salivary gland tumors has 
uncovered some interesting and clinically relevant results.
In conclusion, our 117 patients with salivary 
gland malignancies harbored 354 alterations 
(median = 3 per patient), 240 of which were distinct 
aberrations. The most common aberrations in patients 
with salivary gland tumors were in the TP53 gene, 
followed by alterations in the cyclin pathway and the 
PI3K pathway (PIK3CA, PIK3R1, PTEN or AKT) 
(Table 1 and Figure 1A). Interestingly, in multivariate 
analysis, there was a significant independent association 
between alterations in the TP53 and ERBB2 genes 
(p = 0.01) (Table 2), cyclin pathway and the MDM2 
gene (p = 0.03) (Table 3), and between HRAS and 
the PI3K pathway (p = 0.0001) (Table 4), suggesting 
that dual targeting with cognate inhibitors may be 
necessary to overcome resistance. The vast majority of 
patients (91.5%) had at least one aberration that was 
potentially targetable by an FDA-approved drug or an 
investigational agent in a clinical trial. Indeed, of the 
240 distinct aberrations, 155 (64.6%) were potentially 
actionable. These observations suggest that matching 
patients with appropriately targeted agents is feasible 
and warrants study. However, only 10 of 117 patients 
(8.5%) had a molecular portfolio identical to at least 
one other patient. The latter results are similar to those 
that we reported in metastatic breast cancer, where we 
recently described 131 distinct aberrations in 57 patients 
with no two patients having the same molecular portfolio 
[49–51]. Taken together, these observations suggest 
that customized combination therapy may have the 
potential to provide significant benefit for these patients.
MATERIALS AND METHODS
Patients
We investigated the genomic aberration status of 
patients with salivary gland tumors referred to Foundation 
Medicine (Cambridge, MA) for NGS from October 
2011 to November 2013 (N = 117). We retrospectively 
reviewed the histological types of salivary gland tumors 
and associated genetic aberrations. Here, we report on the 
prevalence and frequencies of these aberrations in salivary 
gland tumors.
Tissue samples and mutational analysis
Available tissues from diagnostic and therapeutic 
procedures were used to assess molecular aberrations. 
Samples from formalin-fixed paraffin-embedded tissue 
were sent for targeted NGS at Foundation Medicine 
(Cambridge, MA). The test sequences the entire coding 
sequence of 182, or more recently 236, cancer-related 
genes plus 47 introns from 19 genes often rearranged 
or altered in cancer to an average depth-of-coverage 
of greater than 250X (http://foundationone.com/docs/
FoundationOne_tech-info-and-overview.pdf).
This method of sequencing allows for detection 
of copy number alterations, gene rearrangements, and 
somatic mutations with 99% specificity and >99% 
sensitivity for base substitutions at ≥5 mutant allele 
frequency and >95% sensitivity for copy number 
alterations. Foundation Medicine uses a threshold of ≥8 
copies for gene amplification. The submitting physicians 
provided specification of tumor types. Next-generation 
sequencing data were collected and interpreted by 
N-of-One, Inc. (Lexington, MA;http://www.n-of-one.
com). Data was analyzed in accordance with UCSD 
IRB guidelines. For the purpose of our analysis, 
“phosphoinositide 3-kinase (PI3K) pathway” alterations 
included alterations of PIK3CA, PIK3RI, PTEN, 
or AKT1/3. Similarly, “cyclin pathway” alterations 
included CCND1, CDK4/6, or CDKN2A/B alterations. 
We have evaluated if certain genomic aberrations were 
actionable or not based on the availability of drug that is 
approved or in clinical trials that targets that aberration 
with low nM IC50 or an antibody that primarily targets 
that abnormality.
Endpoints and statistical methods
Descriptive statistics were used to summarize the 
baseline patient characteristics. The Fisher’s exact test 
was used to assess the association between categorical 
variables in univariate analysis. Multiple logistic 
regression models were used for multivariable analysis. 
All tests were 2-sided. Statistical analyses were carried out 
using GraphPad Prism version 6.0 (San Diego, CA, USA) 
and SPSS version 22.0 (Chicago, IL, USA).
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